Background: The immunogen used for the anti-human Vav-2 SHD region was a his tagged fusion protein Vav-2 corresponding to amino acid sequence 578 - 878 and having a molecular weight of 100kD. Vav-2 has a molecular weight of 100 kD and shares over a 50% homology at the amino acid and nucleic acid level with Vav. Vav-2 is a ubiquitously expressed structural homolog of the Vav protooncogene that is expressed preferentially in hematopoetic cells. Both proteins are comprised of a Dbl- homology ((DH) domain with guanosine nucleotide exchange (GEF) activity exclusively directed towards Rho/Rac GTPases, a pleckstrin homology (PH) domain, a calponin-homology (CH) region, an acidic domain (AD) a zinc finger butterfly motif, two SH3 regions and one SH2 domain. GEF activity of RhoA family G proteins is induced by tyrosine phosphorylation in wild type vav-2, and is constitutively activated in N terminus deleted oncogene forms. Constitutive expression of a Vav-2 oncoprotein may result in morphological alterations including highly enlarged cells in which karyokinesis and cytokinesis frequently are uncoupled.
Immunogen: A his tagged fusion protein Vav-2 corresponding to amino acid sequence 578 - 878 and having a molecular weight of 100kD.
Purification Method: Ammonium Sulfate Precipitation.
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide.
UniProt: P52735 (Human).
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
